Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Flow-Cytometric Expression of Endoglin Assessed in B-Acute Lymphoblastic Leukemia

By LabMedica International staff writers
Posted on 01 Apr 2021
Acute lymphoblastic leukemia (ALL) is a malignant disorder representing clonal expansion and arrest of maturation of lymphoid progenitor cells in the bone marrow, blood, and extramedullary sites. The incidence of ALL generally follows a bimodal distribution, with its first peak occurring in childhood and the second around the age of 50.

CD105 or Endoglin is a homodimeric transmembrane co-receptor that interacts with transforming growth factor-Beta (TGF-β) receptors type I and III, consequently adjusting angiogenesis by regulating proliferation, differentiation, and endothelial cell migration. It is expressed on the surface of endothelial cells, stromal cells, melanocytes, and different hematopoietic cells.

Clinical Scientists at the Tanta University (Tanta, Egypt) included in a study 80 children newly diagnosed with B-acute lymphoblastic leukemia (B-ALL) from June 2017 to August 2020. There were 50 boys (62.5%) and 30 girls (37.5%) with a male to female ratio of 1.6:1, their ages ranged from 1 to 15 years with a median value 7.3 years. Cases were diagnosed based on clinical presentation, complete blood count (CBC), bone marrow (BM) examination, morphological and cytochemical smears as well as immunophenotyping. The CBC was performed on an ERMA PCE-210N cell counter (ERMA Inc, Tokyo, Japan).

Liver and renal function tests, and lactate dehydrogenase enzyme (LDH) on a fully automated chemistry analyzer (Konelab Prime 60i, (Thermo Fisher Scientific, Vantaa, Finland), erythrocyte sedimentation rate (ESR), and cerebrospinal fluid (CSF) cytological examination. Immunophenotyping analysis was done on BM samples collected into EDTA-containing tubes using the four-color flow cytometry Becton Dickinson (BD) FACSCalibur instrument (BD Biosciences, San Diego, CA, USA).

The scientists reported that the mean and standard deviation (SD) of the hemoglobin (Hb) level was 7.9 ± 1.8 (g/dL), blast percentage in peripheral blood 38 ± 23.3 (%), and ESR 82 ± 15.3 (mm/h). The median and range for the total leucocyte count was 20 (1–110) ×103/mm3, platelets count 65 (10–260) ×103/mm3, blast percentage in bone marrow 82.5 (50–98) %, LDH level 822 (340–3,200) IU/L. CD105 was expressed in 41.2% of B-ALL patients. Higher expression of CD105 was observed in high and very high-risk groups. The multivariate analysis considered CD105 positivity as an independent prognostic marker for response to induction therapy. Values higher than 2.5 Specific fluorescence indices (SFIs) and 35% expression were sensitive predictors to induction failure.

The authors concluded that CD105 can be considered a potential marker for the prognosis of pediatric patients with B-ALL, as patients who showed expression higher than 35% and 2.5 SFIs were at higher risk for induction failure and it can serve to optimize treatment decisions. The study was published on March 16, 2021 in the Journal of Blood Medicine.

Related Links:
Tanta University
ERMA
Thermo Fisher Scientific
BD Biosciences



Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Piezoelectric Micropump
Disc Pump
New
Silver Member
ACTH Assay
ACTH ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.